OSE Immunotherapeutics: Combi-TED trial results expected at ESMO 2026
The Nantes-based biotech company announced that the primary results of its phase 2 Combi-TED trial, evaluating Tedopi in metastatic non-small cell lung cancer, will be presented orally at the annual congress of the European Society for Medical Oncology, in Madrid.
Oral presentation selected for the Combi-TED trial
OSE Immunotherapeutics announced on September 23, 2026 that the primary results of the international phase 2 clinical trial Combi-TED, focusing on Tedopi in metastatic non-small cell lung cancer (NSCLC) and sponsored by FoRT, have been selected for an oral presentation at the 2026 ESMO annual congress, scheduled in Madrid from October 23 to 27, 2026.
Federico Cappuzzo, Director of Medical Oncology at the Regina Elena National Cancer Institute in Rome and principal investigator of the trial, will present these results. The presentation is scheduled for October 25, 2026, during a session dedicated to metastatic non-small cell lung cancer.
A second-line trial involving 105 patients in three countries
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Combi-TED is a randomized, open-label, phase 2 trial with three arms. It evaluates Tedopi in combination with the anti-PD1 checkpoint inhibitor Opdivo (nivolumab), with docetaxel, or docetaxel alone (control arm), as second-line treatment.
The trial involves 105 HLA-A2 positive patients with metastatic NSCLC, without EGFR mutations or ALK or ROS1 rearrangements, following first-line chemotherapy-immunotherapy. The primary endpoint is the one-year survival rate. The study is conducted in 23 centers located in France, Italy and Spain.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Guidance from the release
La Société poursuit activement ses interactions avec les investisseurs institutionnels aux États-Unis et en Europe afin d'étendre son horizon de financement au-delà des points d'inflexion de valeur à venir
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
